Control arms are hard to fill and hard on patients
Category: Clinical Trials
Randomizing patients to control slows enrollment, and in serious diseases patients are reluctant to risk assignment to placebo or standard-of-care arms.
Control arms are scientifically necessary but operationally expensive: they increase the number of patients a trial must recruit, and in serious or rare diseases the prospect of randomization to placebo or standard of care deters participation. Design-stage AI approaches — model-informed trial simulation, synthetic data, and prognostic models trained on historical patient data — can support designs that need fewer control-arm patients, subject to regulatory acceptance for the specific context. Sponsors should probe exactly which regulatory precedents a vendor can point to for their therapeutic area.
How AI approaches the control-arm problem
Three distinct approaches exist, and they are often conflated. External control arms use historical trial data or real-world data in place of some or all of a concurrent control group. Prognostic models — sometimes marketed as digital twins — forecast each enrolled participant's expected disease course from historical data, which can increase statistical efficiency and support designs that randomize fewer patients to control. Trial simulation stress-tests design options before the protocol is finalized. Each carries a different evidence burden and a different regulatory conversation. None eliminates the scientific role of randomization; the realistic goal is a design that asks fewer patients to accept control assignment while preserving interpretability.
What to evaluate before buying into these approaches
Regulatory precedent is the entire game, and it is context-specific: acceptance that exists in one indication, phase, or agency does not transfer automatically to yours. Ask vendors for the specific regulatory interactions and submissions their method has supported in your therapeutic area — and treat vague appeals to 'regulatory acceptance' as a red flag. Then probe methodology: the provenance and comparability of the historical data, how the vendor handles differences in standard of care over time, and how their models are validated on data they were not trained on. Your biostatisticians should be in these conversations from the first call.
How teams typically get started
The standard path is conservative: use these methods first in exploratory or supportive analyses — trial simulation during design, a prognostic model as a pre-specified covariate — rather than replacing control patients outright. Early engagement with regulators on the specific proposed use, before committing the pivotal design, is consistently the difference between a productive review and a costly redesign.
AI Use Cases That Address This Problem
- Protocol Design Optimization
Frequently asked questions
What is an external or synthetic control arm?
A comparator group built from data outside the trial itself — prior clinical trials, registries, or real-world data — instead of (or supplementing) concurrently randomized control patients. The scientific challenge is comparability: ensuring differences in populations, era of treatment, and data collection don't bias the comparison.
Will the FDA or EMA accept an external control arm?
Case by case. External controls have been used in regulatory decisions, most often in rare diseases and settings where randomization is infeasible or unethical, and agencies have published guidance on their design. There is no blanket acceptance — early, indication-specific engagement with the agency is essential before building a pivotal strategy around one.
What is a prognostic digital twin in a clinical trial?
A model-generated forecast of how an individual participant would likely progress without the investigational treatment, built from historical patient data. Used as a pre-specified element of the statistical analysis, such forecasts can improve efficiency and reduce the number of patients needed in the control arm — the participant is still real and still randomized.
Do these approaches eliminate the need for randomization?
No. Randomization remains the strongest tool against bias, and regulators treat fully non-randomized evidence with corresponding caution. The practical promise is trials that need fewer control-arm patients — a meaningful gain for enrollment and for patients — not trials with no control at all.